EUVIMEDEUVIMED entdecken
Open Access

Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml−1 to 10 ng ml−1

Chi-Chen Zhang, Xiang Tu, Tian-Hai Lin, Di-Ming Cai, Ling Yang, Shi Qiu, Zhen-Hua Liu, Lu Yang, Qiang Wei

Asian Journal of Andrology · 2023-07 · 25 (4) · 492-498

DOI: 10.4103/aja202288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Andrology, online erschienen am 20.12.2022. Verfasst von Chi-Chen Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We attempted to perform risk categories based on the free/total prostate-specific antigen ratio (%fPSA), prostate-specific antigen (PSA) density (PSAD, in ng ml −2 ), and multiparametric magnetic resonance imaging (mpMRI) step by step, with the goal of determining the best clinical diagnostic strategy to avoid unnecessary tests and prostate biopsy (PBx) in biopsy-naïve men with PSA levels ranging from 4 ng ml −1 to 10 ng ml −1 . We included 439 patients who had mpMRI and PBx between August 2018 and July 2021 (West China Hospital, Chengdu, China). To detect clinically significant prostate cancer (csPCa) on PBx, receiver-operating characteristic (ROC) curves and their respective area under the curve were calculated. Based on %fPSA, PSAD, and Prostate Imaging-Reporting and Data System (PI-RADS) scores, the negative predictive value (NPV) and positive predictive value (PPV) were calculated sequentially. The optimal %fPSA threshold was determined to be 0.16, and the optimal PSAD threshold was 0.12 for %fPSA ³0.16 and 0.23 for %fPSA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMultiparametric Magnetic Resonance ImagingMaleHumansProstate-Specific AntigenMagnetic Resonance ImagingRetrospective StudiesBiopsyImage-Guided Biopsy

Stichwörter der Autor:innen

PSA-derived parametermultiparametric magnetic resonance imagingpredictive valueprostate biopsyprostate cancerprostate-specific antigen

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Ultrasound, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China.

Zitieren

APA

Zhang, C. C., Tu, X., Lin, T. H., Cai, D. M., Yang, L., Qiu, S., Liu, Z. H., Yang, L., & Wei, Q. (2023). Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml−1 to 10 ng ml−1. Asian Journal of Andrology, 25(4), 492-498. https://doi.org/10.4103/aja202288

Vancouver

Zhang CC, Tu X, Lin TH, Cai DM, Yang L, Qiu S, et al. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml−1 to 10 ng ml−1. Asian Journal of Andrology. 2023;25(4):492-498. doi:10.4103/aja202288

BibTeX
@article{Zhang2023,
  author = {Zhang, Chi-Chen and Tu, Xiang and Lin, Tian-Hai and Cai, Di-Ming and Yang, Ling and Qiu, Shi and Liu, Zhen-Hua and Yang, Lu and Wei, Qiang},
  title = {Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml−1 to 10 ng ml−1},
  journal = {Asian Journal of Andrology},
  year = {2023},
  volume = {25},
  number = {4},
  pages = {492--498},
  doi = {10.4103/aja202288}
}
Kostenlos starten →